# Purine and Pyrimidine Synthesis Pathways: A Comprehensive Guide

Nucleotide biosynthesis is a fundamental process that supplies the building blocks for DNA and RNA. Every dividing cell must produce adequate quantities of purine and pyrimidine nucleotides to support genome replication, transcription, and a host of other metabolic functions including energy transfer (ATP, GTP), [signal transduction](/knowledge/molecular-biology/signal-transduction) (cAMP, cGMP), and activated intermediates in biosynthetic reactions (UDP-glucose, S-adenosylmethionine). The pathways that generate these molecules are ancient, highly conserved, and exquisitely regulated. Understanding them requires a clear grasp of two distinct routes: the *de novo* pathways, which build the nitrogenous base rings from small precursors, and the salvage pathways, which recycle preformed bases and nucleosides released from nucleic acid turnover.

## Introduction to Nucleotide Biosynthesis

Purines (adenine and guanine) are characterized by a fused six-membered and five-membered ring system. Pyrimidines (cytosine, thymine, and uracil) possess a single six-membered ring. In DNA, the [Purine Always Pair with Pyrimidine](/knowledge/molecular-biology/purine-always-pair-with-pyrimidine) rule dictates that adenine pairs with thymine via two hydrogen bonds and guanine pairs with cytosine via three hydrogen bonds. This structural complementarity is essential for the double helix and for faithful replication. The chemical differences between these bases are detailed further in [Purine Pyrimidine Bases](/knowledge/molecular-biology/purine-pyrimidine-bases).

### De novo vs. Salvage Pathways

The *de novo* pathways synthesize nucleotides from simple precursors: amino acids (glutamine, glycine, aspartate), carbon dioxide, tetrahydrofolate derivatives, and ribose-5-phosphate. These pathways are energetically expensive—synthesis of one purine nucleotide consumes approximately six ATP equivalents. The salvage pathways are far more economical, requiring only a phosphoribosyl donor (PRPP) and a single enzyme to convert a free base into its nucleotide monophosphate. Most cells use both routes, with the relative contribution depending on tissue type and metabolic state. Erythrocytes and brain tissue rely heavily on salvage because they lack the full complement of de novo enzymes, whereas the liver is the primary site of de novo synthesis for export to other tissues.

### Cellular Significance

The importance of these pathways cannot be overstated. Genetic defects in [nucleotide synthesis](/knowledge/molecular-biology/nucleotide-synthesis) cause severe immunodeficiency, neurological dysfunction, and developmental abnormalities. Conversely, rapidly dividing cancer cells have elevated [nucleotide synthesis](/knowledge/molecular-biology/nucleotide-synthesis) rates, making these pathways prime targets for chemotherapeutic agents. A thorough understanding of the enzymes, intermediates, and regulatory logic of purine and pyrimidine synthesis is therefore essential for both basic biochemistry and clinical medicine.

## De Novo Purine Synthesis Pathway

The de novo purine synthesis pathway is unique in that the purine ring is assembled directly on a ribose-phosphate scaffold. The starting material is ribose-5-phosphate, derived from the pentose phosphate pathway. The end product of the pathway is inosine monophosphate (IMP), which serves as the branch point for synthesis of adenosine monophosphate (AMP) and guanosine monophosphate (GMP). The entire pathway consists of ten enzymatic steps, each catalyzed by a distinct enzyme.

### Formation of 5-Phosphoribosyl-1-pyrophosphate (PRPP)

The pathway begins with the activation of ribose-5-phosphate. The enzyme **ribose-phosphate diphosphokinase** (also called PRPP synthetase) transfers a pyrophosphate group from ATP to the C1 hydroxyl of ribose-5-phosphate, yielding **5-phosphoribosyl-1-pyrophosphate (PRPP)** and AMP. This reaction requires magnesium ions as a cofactor.

PRPP is a central metabolite not only for purine synthesis but also for pyrimidine synthesis and salvage pathways. The enzyme is allosterically inhibited by purine nucleotides (ADP and GDP), providing a feedback mechanism that links PRPP availability to the cellular nucleotide pool.

### Commitment Step: Amidophosphoribosyltransferase

The first committed step of de novo purine synthesis is catalyzed by **amidophosphoribosyltransferase** (also known as glutamine phosphoribosylpyrophosphate amidotransferase, GPAT). This enzyme replaces the pyrophosphate group at C1 of PRPP with an amino group derived from glutamine, producing **5-phosphoribosylamine (5-PRA)**. The reaction releases pyrophosphate and glutamate.

This step is the rate-limiting reaction of the entire pathway. The enzyme is subject to feedback inhibition by AMP and GMP, and it is activated by PRPP. The \(K_m\) for glutamine is approximately 1.6 mM, and the enzyme has an absolute requirement for magnesium ions. The reaction is thermodynamically favorable due to the hydrolysis of pyrophosphate.

### Assembly of the Purine Ring

The remaining eight steps build the purine ring system onto the 5-PRA scaffold. Each step adds specific atoms that ultimately form the fused bicyclic structure. The numbering of the purine ring is critical for tracking atom origins: atoms 1, 3, and 9 come from glutamine; atoms 2 and 8 come from formate (via tetrahydrofolate); atom 4, 5, and 7 come from glycine; and atom 6 comes from carbon dioxide.

The sequence of reactions is as follows:

1. **Glycine addition**: Glycineamide ribonucleotide synthetase (GARS) adds glycine to 5-PRA using ATP, forming glycinamide ribonucleotide (GAR).
2. **Formylation**: GAR transformylase transfers a formyl group from N10-formyltetrahydrofolate to the amino group of glycine, yielding formylglycinamide ribonucleotide (FGAR).
3. **Amidation**: FGAM synthetase (FGAMS) converts FGAR to formylglycinamidine ribonucleotide (FGAM) using glutamine as the nitrogen donor and ATP for activation.
4. **Ring closure**: AIR synthetase (AIRS) catalyzes an ATP-dependent dehydration that closes the imidazole ring, forming 5-aminoimidazole ribonucleotide (AIR).
5. **Carboxylation**: AIR carboxylase (AIRC) adds a carboxyl group at position 6, producing carboxyaminoimidazole ribonucleotide (CAIR). This reaction uses bicarbonate and ATP.
6. **Aspartate addition**: SAICAR synthetase adds aspartate to CAIR, forming succinylaminoimidazolecarboxamide ribonucleotide (SAICAR).
7. **Fumarate release**: Adenylosuccinate lyase (ASL) removes fumarate from SAICAR, yielding aminoimidazolecarboxamide ribonucleotide (AICAR).
8. **Second formylation**: AICAR transformylase transfers another formyl group from N10-formyltetrahydrofolate, producing formylaminoimidazolecarboxamide ribonucleotide (FAICAR).
9. **Final ring closure**: Inosine monophosphate cyclohydrolase (IMPCH) catalyzes the dehydration that closes the second ring, yielding **inosine monophosphate (IMP)**.

In humans, steps 6 and 7 are catalyzed by a bifunctional enzyme, and steps 9 and 10 are catalyzed by a single bifunctional polypeptide. This organization increases metabolic efficiency by channeling intermediates between active sites.

### Conversion of IMP to AMP and GMP

IMP is the branch point for the synthesis of AMP and GMP. These conversions are mutually exclusive and independently regulated.

**To AMP**: Adenylosuccinate synthetase converts IMP to adenylosuccinate by adding aspartate, using GTP as the energy source. Adenylosuccinate lyase (the same enzyme that acts in the de novo pathway) then removes fumarate to yield AMP.

**To GMP**: IMP dehydrogenase (IMPDH) oxidizes IMP to xanthosine monophosphate (XMP), using NAD+ as the electron acceptor. This is the rate-limiting step for GMP synthesis. GMP synthetase then aminates XMP using glutamine as the nitrogen donor and ATP for activation, producing GMP.

The reciprocal regulation of these branches is notable: GTP is required for AMP synthesis, and ATP is required for GMP synthesis. This ensures that the cellular pools of adenine and guanine nucleotides remain balanced.

## De Novo Pyrimidine Synthesis Pathway

Unlike purine synthesis, the pyrimidine ring is assembled first as a free molecule and then attached to ribose-5-phosphate. The pathway is shorter (six enzymatic steps) and culminates in the production of uridine monophosphate (UMP), which is then converted to other pyrimidine nucleotides.

### Carbamoyl Phosphate Formation

The pathway begins in the cytosol with the synthesis of **carbamoyl phosphate** from glutamine, bicarbonate, and two molecules of ATP. This reaction is catalyzed by **carbamoyl phosphate synthetase II (CPS II)**, a cytosolic enzyme distinct from the mitochondrial CPS I involved in the urea cycle. CPS II uses glutamine as the nitrogen donor (whereas CPS I uses ammonia) and is the rate-limiting enzyme of the pyrimidine pathway.

The reaction proceeds in three steps: activation of bicarbonate by ATP to form carboxyphosphate, reaction with glutamine to form carbamate, and phosphorylation of carbamate by a second ATP to yield carbamoyl phosphate. The enzyme is activated by PRPP and inhibited by UTP (the end product of the pathway).

### Formation of Orotate and Orotidine-5'-monophosphate (OMP)

Carbamoyl phosphate then condenses with aspartate in a reaction catalyzed by **aspartate transcarbamoylase (ATCase)**. This enzyme, which is the committed step of the pathway, produces **N-carbamoylaspartate**. In bacteria, ATCase is a classic model for allosteric regulation, being inhibited by CTP and activated by ATP. In mammals, the regulation is less dramatic but still significant.

N-carbamoylaspartate undergoes a dehydration reaction catalyzed by **dihydroorotase** to form **dihydroorotate**, which contains the six-membered pyrimidine ring.

The next step is unusual: **dihydroorotate dehydrogenase (DHODH)** is located on the outer surface of the inner mitochondrial membrane and uses ubiquinone (coenzyme Q) as the electron acceptor to oxidize dihydroorotate to **orotate**. This is the only mitochondrial step in the pathway.

Orotate then reacts with PRPP in a reaction catalyzed by **orotate phosphoribosyltransferase (OPRT)**, producing **orotidine-5'-monophosphate (OMP)** and releasing pyrophosphate. This is the step where the pyrimidine ring is attached to the ribose-phosphate moiety.

### Decarboxylation to UMP

**OMP decarboxylase** catalyzes the final step: decarboxylation of OMP to yield **uridine monophosphate (UMP)**. This enzyme is one of the most catalytically efficient enzymes known, with a rate enhancement of approximately \(10^{17}\)-fold over the uncatalyzed reaction. In humans, OPRT and OMP decarboxylase exist as a bifunctional enzyme called UMP synthase.

### Conversion to CTP and dTMP

UMP is phosphorylated to UDP and then to UTP by specific nucleoside monophosphate and diphosphate kinases. UTP is then converted to **cytidine triphosphate (CTP)** by **CTP synthetase**, which aminates UTP using glutamine as the nitrogen donor and ATP for energy.

The synthesis of **deoxythymidine monophosphate (dTMP)** requires a separate pathway. First, UDP is reduced to dUDP by **ribonucleotide reductase**, an enzyme that converts ribonucleoside diphosphates to their 2'-deoxy counterparts. dUDP is then phosphorylated to dUTP and subsequently dephosphorylated to dUMP. Alternatively, dUMP can be formed by deamination of dCMP. The key enzyme **thymidylate synthase** then methylates dUMP to dTMP, using N5,N10-methylene-tetrahydrofolate as both the methyl donor and the reductant. This reaction oxidizes tetrahydrofolate to dihydrofolate, which must be reduced back to tetrahydrofolate by **dihydrofolate reductase (DHFR)** for the cycle to continue. This is the target of the chemotherapeutic drug methotrexate.

## Regulation of Purine and Pyrimidine Synthesis

The regulation of nucleotide synthesis is designed to maintain balanced pools of all four ribonucleoside triphosphates. Imbalances can cause mutations through misincorporation during [DNA replication](/blog/guides/dna-replication) and can disrupt signaling pathways.

### Purine Regulation

The primary regulatory point is **amidophosphoribosyltransferase**, which is inhibited by AMP and GMP (the end products) and activated by PRPP. The inhibition is synergistic: AMP and GMP together inhibit more effectively than either alone. Additionally, the conversion of IMP to AMP is inhibited by AMP, and the conversion of IMP to GMP is inhibited by GMP. This ensures that when one purine nucleotide is abundant, the pathway diverts IMP toward the other.

PRPP synthetase is also regulated by purine nucleotides (ADP and GDP), providing an additional layer of control upstream of the committed step.

### Pyrimidine Regulation

**Carbamoyl phosphate synthetase II** is the primary regulatory enzyme, inhibited by UTP and activated by PRPP. In bacteria, ATCase is the main regulatory point, but in mammals, CPS II carries this role. The enzyme is also subject to activation by ATP, which signals high energy status and the need for [RNA synthesis](/blog/guides/rna-synthesis).

### Cross-Pathway Regulation

The purine and pyrimidine pathways are not independent. PRPP is a shared substrate, and its concentration reflects the overall demand for nucleotides. High PRPP levels activate both pathways, while low levels slow both. Additionally, ATP and GTP (purines) are required for pyrimidine synthesis, and UTP and CTP (pyrimidines) are required for purine synthesis. This mutual dependence ensures that neither pathway outpaces the other.

## Salvage Pathways and Interconversion

Salvage pathways recycle free bases and nucleosides generated during nucleic acid turnover. These pathways are energetically favorable and are particularly important in tissues with limited de novo capacity.

### Purine Salvage

The key enzyme is **hypoxanthine-guanine phosphoribosyltransferase (HGPRT)**, which catalyzes the transfer of phosphoribose from PRPP to hypoxanthine (forming IMP) or to guanine (forming GMP). A second enzyme, **adenine phosphoribosyltransferase (APRT)**, performs the analogous reaction for adenine, producing AMP. Both enzymes are inhibited by their respective nucleotide products.

The importance of HGPRT is underscored by the severe consequences of its deficiency (Lesch-Nyhan syndrome, discussed below). Purine nucleosides (adenosine, guanosine) can also be salvaged by **purine nucleoside phosphorylase (PNP)**, which cleaves the glycosidic bond to release the base and ribose-1-phosphate.

### Pyrimidine Salvage

Pyrimidine salvage is less critical than purine salvage because pyrimidines can be synthesized de novo in most tissues. The enzyme **uridine-cytidine kinase** phosphorylates uridine and cytidine to their monophosphates using ATP. Thymidine is phosphorylated by **thymidine kinase**, an enzyme that is induced during the S phase of the [cell cycle](/blog/guides/cell-cycle) and is a target for antiviral and anticancer drugs.

### Nucleotide Kinases

Once a nucleoside monophosphate is formed (by either de novo synthesis or salvage), it must be phosphorylated to the di- and triphosphate levels. **Nucleoside monophosphate kinases** (e.g., adenylate kinase, guanylate kinase) transfer a phosphate from ATP to the monophosphate, yielding the diphosphate. **Nucleoside diphosphate kinase** then converts diphosphates to triphosphates, using ATP as the phosphate donor. This enzyme has broad specificity and can phosphorylate any nucleoside diphosphate.

## Clinical Relevance and Disorders

Defects in nucleotide synthesis pathways cause a range of human diseases, and the pathways are exploited for therapeutic intervention in cancer and infectious disease.

### Lesch-Nyhan Syndrome

Lesch-Nyhan syndrome is caused by a deficiency in **HGPRT**. Because hypoxanthine and guanine cannot be salvaged, PRPP accumulates and is channeled into de novo purine synthesis, leading to overproduction of uric acid. Patients present with hyperuricemia, gout-like arthritis, kidney stones, and characteristic neurological symptoms including intellectual disability, self-injurious behavior (biting of lips and fingers), and dystonia. The neurological basis is not fully understood but may relate to altered GTP levels affecting dopamine signaling in the basal ganglia.

### Immunodeficiency

**Adenosine deaminase (ADA) deficiency** causes severe combined immunodeficiency (SCID). ADA converts adenosine to inosine; its deficiency leads to accumulation of adenosine and deoxyadenosine. Deoxyadenosine is phosphorylated to dATP, which inhibits ribonucleotide reductase and blocks DNA synthesis. Because T cells and B cells undergo rapid proliferation during immune responses, they are particularly vulnerable. ADA deficiency accounts for approximately 15% of SCID cases and is treatable by enzyme replacement therapy or [gene therapy](/blog/guides/gene-therapy).

**Purine nucleoside phosphorylase (PNP) deficiency** causes a less severe but still significant immunodeficiency, primarily affecting T cells. PNP deficiency leads to accumulation of deoxyguanosine, which is converted to dGTP, also inhibiting ribonucleotide reductase.

### Orotic Aciduria

Orotic aciduria is caused by deficiency of **UMP synthase** (the bifunctional enzyme with OPRT and OMP decarboxylase activities). Patients cannot convert orotate to UMP, so orotate accumulates and is excreted in the urine (giving the condition its name). The lack of pyrimidine nucleotides causes megaloblastic anemia and developmental delay. Treatment with oral uridine bypasses the block, providing a salvage pathway for pyrimidine synthesis.

### Cancer Therapy

Nucleotide synthesis inhibitors are among the most widely used chemotherapeutic agents. The rationale is that rapidly dividing cancer cells require large quantities of nucleotides for [DNA replication](/blog/guides/dna-replication), and inhibiting their synthesis preferentially kills these cells.

Key examples include:

- **Methotrexate**: Inhibits dihydrofolate reductase, depleting tetrahydrofolate and blocking both purine synthesis (formyl group transfer) and dTMP synthesis.
- **5-Fluorouracil (5-FU)**: Metabolized to 5-FdUMP, which irreversibly inhibits thymidylate synthase.
- **6-Mercaptopurine (6-MP)**: Converted to 6-thioIMP, which inhibits de novo purine synthesis at multiple steps.
- **Hydroxyurea**: Inhibits ribonucleotide reductase by quenching the tyrosyl radical in its active site.

These drugs are effective but have significant side effects because they also affect normal dividing cells, particularly in the bone marrow and gastrointestinal tract.

## Methods Used to Study Nucleotide Synthesis

Understanding how these pathways were elucidated and how they are studied today requires knowledge of several experimental approaches.

### Radioactive Labeling

The classic experiments that mapped the origins of purine ring atoms used radioactive precursors. By feeding cells or animals isotopically labeled glycine, formate, or carbon dioxide and then degrading the isolated purines to identify which atoms carried the label, researchers could assign each atom to its precursor. For example, feeding \(^{14}\)C-labeled glycine resulted in labeling of positions 4 and 5 of the purine ring. Similar approaches with \(^{15}\)N-labeled glutamine identified positions 3 and 9.

Modern versions of this approach use stable isotopes such as \(^{13}\)C and \(^{15}\)N, detected by mass spectrometry. This allows metabolic flux analysis, where the rate of incorporation of label into downstream metabolites reveals pathway activity in living cells.

### Enzyme Kinetics

Individual enzymes are studied by measuring their kinetic parameters. Typical assays involve incubating the purified enzyme with its substrates in a buffered solution (e.g., 50 mM Tris-HCl, pH 7.5, containing 5 mM MgCl\(_2\)) at 37°C, then quenching the reaction at various time points and quantifying product formation by HPLC or spectrophotometry. The \(K_m\) and \(V_{max}\) values obtained from these experiments inform our understanding of enzyme regulation and inhibition.

### Gene Knockout Studies

Genetic manipulation allows researchers to assess the physiological role of specific enzymes. In yeast, gene deletion is straightforward, and the resulting growth phenotypes reveal which pathways are essential under various conditions. In mice, conditional knockouts enable tissue-specific studies. For example, liver-specific knockout of amidophosphoribosyltransferase in mice causes a dramatic reduction in circulating uric acid and alters energy metabolism, demonstrating the central role of this enzyme in purine homeostasis.

## Common Pitfalls and Study Tips

Students frequently encounter specific difficulties when learning these pathways. Recognizing these pitfalls can save considerable time and frustration.

### Confusing Purine and Pyrimidine Atoms

A common error is confusing which atoms come from which precursors. A useful mnemonic: glycine provides atoms 4, 5, and 7 of the purine ring; glutamine provides atoms 3 and 9; formate provides atoms 2 and 8; and CO\(_2\) provides atom 6. Drawing the ring and labeling each atom as you learn the pathway is the most reliable way to internalize this information.

### Overlooking Regulation

Many students memorize the reactions but neglect the regulatory logic. The regulation is not arbitrary—it follows the principles of feedback inhibition and balanced production. Ask yourself: "If the cell has too much ATP, which enzyme should be inhibited?" The answer is amidophosphoribosyltransferase. "If the cell needs more GTP, which branch should be activated?" The answer is the IMP to GMP branch. Understanding the logic makes the details easier to remember.

### Memorization Aids

The ten steps of purine synthesis can be memorized using the mnemonic "**G**ood **G**uy **F**inds **A** **C**ar **S**omewhere **A**nd **F**inds **I**t": Glycine addition, GAR formylation, FGAM synthesis, AIR synthesis, CAIR synthesis, SAICAR synthesis, AICAR formation, FAICAR formation, IMP formation. For pyrimidine synthesis, the sequence is simpler: carbamoyl phosphate, carbamoylaspartate, dihydroorotate, orotate, OMP, UMP.

Another common error is forgetting that the pyrimidine ring is synthesized first and then attached to ribose, whereas the purine ring is built on the ribose. Visualizing these different strategies helps prevent confusion.

## Frequently Asked Questions

### What is the difference between purine and pyrimidine synthesis?

Purine synthesis builds the double-ring structure directly onto ribose-5-phosphate, requiring ten enzymatic steps to produce IMP, which is then converted to AMP and GMP. Pyrimidine synthesis first assembles the single ring as a free molecule (orotate), then attaches it to ribose-5-phosphate, requiring six steps to produce UMP, which is then converted to CTP and dTMP. Purine synthesis uses glutamine, glycine, formate, and CO\(_2\) as precursors; pyrimidine synthesis uses carbamoyl phosphate and aspartate.

### Which enzyme is the rate-limiting step in purine synthesis?

Amidophosphoribosyltransferase (GPAT), which converts PRPP to 5-phosphoribosylamine, is the rate-limiting enzyme. It is inhibited by AMP and GMP and activated by PRPP.

### What is the committed step in pyrimidine synthesis?

In mammals, the committed step is catalyzed by carbamoyl phosphate synthetase II, which produces carbamoyl phosphate. In bacteria, the committed step is aspartate transcarbamoylase, which produces N-carbamoylaspartate.

### How are purine and pyrimidine synthesis regulated?

Purine synthesis is regulated primarily at amidophosphoribosyltransferase by feedback inhibition from AMP and GMP. Pyrimidine synthesis is regulated at carbamoyl phosphate synthetase II by inhibition from UTP and activation by PRPP. The two pathways are coordinated through shared use of PRPP and through the requirement for purine nucleotides in pyrimidine synthesis and vice versa.

### What is the role of PRPP in nucleotide synthesis?

PRPP (5-phosphoribosyl-1-pyrophosphate) is the activated ribose-phosphate donor used in both de novo and salvage pathways. It is the substrate for amidophosphoribosyltransferase in purine synthesis, for orotate phosphoribosyltransferase in pyrimidine synthesis, and for HGPRT and APRT in salvage reactions.

### What is Lesch-Nyhan syndrome?

Lesch-Nyhan syndrome is an X-linked recessive disorder caused by deficiency of hypoxanthine-guanine phosphoribosyltransferase (HGPRT). It is characterized by hyperuricemia, gout, kidney stones, intellectual disability, and self-injurious behavior. The overproduction of uric acid results from elevated PRPP levels driving excessive de novo purine synthesis.

### Why are nucleotide synthesis inhibitors used in cancer chemotherapy?

Cancer cells divide rapidly and require large quantities of nucleotides for DNA replication. Inhibiting nucleotide synthesis preferentially kills dividing cells over quiescent cells. Drugs such as methotrexate (inhibits DHFR), 5-fluorouracil (inhibits thymidylate synthase), and 6-mercaptopurine (inhibits de novo purine synthesis) exploit this vulnerability.

## Key Takeaways

- Purines are synthesized as a ring built onto ribose-5-phosphate, while pyrimidines are synthesized as a free ring that is later attached to ribose.
- The rate-limiting enzyme of purine synthesis is amidophosphoribosyltransferase; the rate-limiting enzyme of pyrimidine synthesis is carbamoyl phosphate synthetase II.
- PRPP is the central activated ribose donor for both de novo and salvage pathways.
- The pathways are regulated by feedback inhibition from end products, with reciprocal control ensuring balanced purine and pyrimidine pools.
- Salvage pathways, particularly via HGPRT and APRT, recycle free bases and are essential in tissues with limited de novo capacity.
- Defects in nucleotide synthesis cause severe diseases including Lesch-Nyhan syndrome, SCID, and orotic aciduria.
- Nucleotide synthesis inhibitors are cornerstone drugs in cancer chemotherapy, targeting rapidly dividing cells.

## Further Reading

- Robinson JL, Larson BL. *Nucleotide inhibition of post-orotate pyrimidine synthesis pathway enzymes of bovine mammary tissue*. Journal of dairy science. 1974. [PubMed 4430767](https://doi.org/10.3168/jds.S0022-0302(74)85075-7)
- Wang Y et al. *Cross Talk between Nucleotide Synthesis Pathways with Cellular Immunity in Constraining Hepatitis E Virus Replication*. Antimicrobial agents and chemotherapy. 2016. [PubMed 26926637](https://doi.org/10.1128/AAC.02700-15)
- Kim J et al. *CPS1 maintains pyrimidine pools and DNA synthesis in KRAS/LKB1-mutant lung cancer cells*. Nature. 2017. [PubMed 28538732](https://doi.org/10.1038/nature22359)
- Hernandez DM et al. *Purine and pyrimidine synthesis differently affect the strength of the inoculum effect for aminoglycoside and β-lactam antibiotics*. Microbiology spectrum. 2024. [PubMed 39436125](https://doi.org/10.1128/spectrum.01895-24)
- Zöllner N. *Purine and pyrimidine metabolism*. The Proceedings of the Nutrition Society. 1982. [PubMed 6184723](https://doi.org/10.1079/pns19820048)
- Becker S et al. *Unified prebiotically plausible synthesis of pyrimidine and purine RNA ribonucleotides*. Science (New York, N.Y.). 2019. [PubMed 31604305](https://doi.org/10.1126/science.aax2747)

## Related Topics

- [Nucleotide Synthesis](/knowledge/molecular-biology/nucleotide-synthesis)
- [DNA Supercoiling](/knowledge/molecular-biology/dna-supercoiling)
- [Chromosome Structure](/knowledge/molecular-biology/chromosome-structure)

## Related Clinical & Scientific Guides

* [MAPK Pathway: Mechanism, Function, and Clinical Relevance](/knowledge/molecular-biology/mapk-pathway)
* [Mammalian Cell Culture Bioreactors: A Practical Guide](/knowledge/molecular-biology/mammalian-cell-culture-bioreactor)
* [Nucleotide Formation: Biosynthesis and Assembly of DNA/RNA Building Blocks](/knowledge/molecular-biology/nucleotide-formation)